Our new research focuses on patient adoption of services ranging from diagnosis and treatment choices to information on the medical and financial aspects of care. We found that the current model for how pharma companies engage with HCPs and patients has hit its limit.
In our examination of all this data, we looked to answer this question: What can be done to better connect patients to the services they need? In this report, we explore key findings in our survey and propose how pharma companies can move the needle by fine tuning their programs to raise awareness and use of patient services.
Eighty percent of patients surveyed rated the services they used as valuable or extremely valuable. However, very few are aware of them.
Our research found that the patient services signal is getting lost, the engagement model with patients and HCPs needs to be strengthened, and patients are ready to receive care and services through new, convenient channels. How can pharma companies tune in?
Design patient services for value and demonstrate that value to HCPs. Consider holistic care as a structural element that improves patient outcomes.
Cut through the noise and simplify service choice with coordinated delivery and an integrated service model – all with the patient at the core.
Create surround sound with clear messages and relevant channels. Partner with others in the healthcare ecosystem to meet patients where they are.
Harmonize with HCP workflows and patient lifestyles, using communication channels and care to capitalize on the digital shift accelerated by COVID-19.
Ensure you have the right hits for the moment. Modernize modes of communication and care. Capitalize on the digital shift accelerated by COVID-19.
Take advantage of the heightened interest in the use of technology, and ability to use data to personalize services, to power hyper-relevant digitally enabled patient services.